Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

• ClinicalTrials.gov Identifier: NCT00033371
• Recruitment Status: Completed
• First Posted: January 27, 2003
• Results First Posted: February 4, 2015
• Last Update Posted: September 29, 2020
• Sponsor: National Cancer Institute (NCI)
• Information provided by (Responsible Party): National Cancer Institute (NCI)

Tracking Information

• First Submitted Date: April 9, 2002
• First Posted Date: January 27, 2003
• Results First Submitted Date: January 26, 2015
• Results First Posted Date: February 4, 2015
• Last Update Posted Date: September 29, 2020
• Actual Study Start Date: December 13, 2001
• Actual Primary Completion Date: February 24, 2009 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 8, 2020)

• Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum [ Time Frame: Baseline up to 6 months ]
  Differences between average treatment effects of two study arms tested using two-sided type I error rate of 5% in two-sample t-test. If model assumptions not met by data or transformations of data, appropriate nonparametric tests (e.g. Wilcoxon rank sums test) were used to compare treatment arms - Percent change of polyp counts from baseline to 6 months, ie [(6 months - baseline) x 100]/baseline (%). For each participant, first were matched polyps between baseline & 6 months by region and landmark and summed over all matched regions on number of polyps >2 mm to calculate total number of polyps >2 mm at baseline & 6 months, respectively. For participants refusing exit colonoscopy, 0% change entered as primary endpoint. Defined ITT All: All patients; if 6-month polyp counts missing = 0% change; ITT Measurable: All participants with baseline & 6 month polyp counts; ITT Evaluable: ITT Measurable participants who also took 80% of treatment, both overall as well as during final 60 days.
• Number of Participants With Adverse Events Occurring at a Frequency of 5% or Grade 3 and Higher [ Time Frame: 6 months ]
  To determine the relative tolerability and safety of celecoxib + DFMO in FAP study participants. Includes only adverse events that occurred in at least 5% of the patients or a patient exhibited at least 1 grade 3 toxicity.

• Original Primary Outcome Measures: Not Provided

Current Secondary Outcome Measures (submitted: September 8, 2020)

• Percentage Change in Global Colorectal Polyps Burden [ Time Frame: 6 months ]
  Percentage Change in Global Colorectal Polyps burden
• Percent Change in the Area of Plaque-like Duodenal Polyps [ Time Frame: 6 months ]

• Original Secondary Outcome Measures: Not Provided

Current Other Pre-specified Outcome Measures (submitted: September 8, 2020)

• Global Duodenal Polyp Burden [ Time Frame: 6 months ]
• Percent Change in Polyp Size in Focal Area(s) of the Colorectum [ Time Frame: Baseline up to 2 months after completion of study treatment ]

• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
• Official Title: A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients
• Brief Summary: This randomized phase II trial studies how well giving celecoxib with or without eflornithine works in preventing colorectal cancer in patients with familial adenomatous polyposis. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib and eflornithine may keep cancer from forming in patients with familial adenomatous polyposis.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the relative efficacy of celecoxib plus eflornithine (DFMO) versus celecoxib plus DFMO placebo in participants with familial adenomatous polyposis (FAP), as evidenced by the percent change from baseline in the number of polyps in focal area(s) of the colorectum in participants having 5 or more >= 2mm colorectal polyps with or without duodenal polyps at baseline.

II. To determine the relative tolerability and safety of celecoxib + DFMO in FAP study participants.

SECONDARY OBJECTIVES:

I. To determine the percent change in polyp size in focal area(s) of the colorectum II. To determine the change in global colorectal polyp burden III. To determine the percent change in the area of plaque-like duodenal polyps in participants presenting with duodenal disease at baseline.

IV. To analyze the effects of these agents on the following panel of mucosal biomarkers: antigen identified by monoclonal antibody Ki-67 (Ki-67), mitotic index (number and spatial distribution of mitoses), phosphorylated histone H3, cyclin-dependent kinase inhibitor 1A (p21/WAF1/Cip1), apoptosis (Terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL]), apoptotic index, BCL2-associated X protein (Bax), B-cell CLL/lymphoma 2 (Bcl-2) and measurement of drug effects in colonic polyp and normal tissue cyclooxygenase (cyclooxygenase-1 [COX-1], cyclooxygenase-2 [COX-2]) protein levels, prostaglandin E2 (PGE2), ornithine decarboxylase and polyamines.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive celecoxib orally (PO) twice daily (BID) and placebo PO daily.

ARM II: Patients receive celecoxib PO BID and eflornithine PO daily.

In both arms, treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.

After completion of just treatment, patients are followed up at 1-2 months.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment

Condition

• Colorectal Cancer
• Familial Adenomatous Polyposis

Intervention

• Drug: Celecoxib
  Given 400 mg PO twice a day
  Other Names:

  • Celebrex
  • SC-58635
• Other: Placebo
  Given PO to match DFMO
  Other Name: PLCB
• Drug: eflornithine
  Given PO at 0.5 gm/m^2/day rounded down to the nearest 250 mg dose (BSA of < 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of > 2.6 = 1,250 mg/day).
  Other Names:

  • 2-difluoromethylornithine
  • DFMO
  • difluromethylornithine
• Other: Laboratory biomarker analysis
  Correlative studies
• Other: Questionnaire administration
  Ancillary studies
  Other Name: Survey

Study Arms

• Active Comparator: Arm I: Celecoxib and Placebo
  Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
  Interventions:

  • Drug: Celecoxib
  • Other: Placebo
  • Other: Laboratory biomarker analysis
  • Other: Questionnaire administration
• Experimental: Arm II: Celecoxib and Eflornithine
  Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
  Interventions:

  • Drug: Celecoxib
  • Drug: eflornithine
  • Other: Laboratory biomarker analysis
  • Other: Questionnaire administration

• Publications *: Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb;65(2):286-95. doi: 10.1136/gutjnl-2014-307235. Epub 2015 Mar 19.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: September 8, 2020): 205
• Original Enrollment: Not Provided
• Actual Study Completion Date: March 24, 2009
• Actual Primary Completion Date: February 24, 2009 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• REGISTRATION INCLUSION CRITERIA:

• Diagnosis of FAP based on any of the following will be acceptable:

  • > 100 polyps or

  • > 10 polyps and age < 40 years, or > 25 polyps and age > 40 years and characteristic family history (autosomal dominant pattern) including:

    • > 100 polyps in a first degree family member or
    • > 25 polyps in two relatives in two generations, including a first degree family member or
    • Genetic diagnosis in a relative or
  • Genetic diagnosis by in vitro synthesized protein (IVSP) or similar assay
• Willingness to abstain from use of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, for the duration of the study; a cardio-protective dose of aspirin (>= 80 mg) may be permitted but must be reviewed/approved by principal investigator (PI)
• If participant is female and of child bearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception (e.g. abstinence, condom, intrauterine device [IUD], birth control pill, diaphragm and spermicide gel combination) since her last menses and will use adequate contraception during the study, is not lactating, and agrees to undergo a serum pregnancy test at baseline, month 3 and month 6; sexually active males must agree to use an accepted and effective method of contraception
• Colon polyp status: the participant has an endoscopically assessable colonic and/or rectal segment
• Participant has no clinically significant hearing loss that is defined by the patient reporting that their hearing loss affects their everyday life and/or wears a hearing aide
• Participants whose air conduction pure tone audiogram reveals a deficit that differs from the age specific norm by less than 30 dB when averaged across two contiguous test frequencies in either ear are eligible, as long as no self-reported hearing deficit or tinnitus is present
• Willingness and ability to sign informed consent
• RANDOMIZATION INCLUSION CRITERIA:
• The individual has assessable colonic polyps remaining in the colon or rectum post baseline colonoscopy or flexible sigmoidoscopy

• Potential participants must have the following colonic or rectal polyp burden at the conclusion of the baseline endoscopy:

  • Rectum:

    • Five or more polyps >= 2 mm diameter

  • Colon:

    • Five or more polyps >= 2 mm diameter including:

      • Three quantifiable polyps > 3 mm diameter, or two quantifiable polyps > 5 mm diameter
      • In the colon, quantifiable polyps are defined as being within a composite "cloverleaf" photograph that includes a tattoo, the appendix, or the ileocecal valve

Exclusion Criteria:

• REGISTRATION EXCLUSION CRITERIA:
• Anticipated colectomy within eight months of randomization
• History of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs or salicylates
• Chronic use of NSAIDs, including aspirin or Celebrex, at any dose during the six months prior to study entry will require a three-month washout period prior to eligibility beginning with the time of the patient's last dose; participants must voluntarily agree to be off all NSAIDs for three months prior to study enrollment; a cardio-protective dose of aspirin (>= 80 mg) may be permitted but must be reviewed/approved by PI
• The use of fluconazole, lithium or chronic use of adrenocorticosteroids
• History in the past year of discrete gastric or duodenal ulcer of size > 5 mm, except that those with a history of Helicobacter pylori related peptic ulcer disease will become eligible for study upon successfully completing antibiotic treatment of Helicobacter pylori
• History of invasive carcinoma in the past five years other than resected Duke's A/B1 colon cancer or resected non-melanomatous skin cancer
• Partial or complete colectomy within 12 months prior to enrollment
• Inability to return for follow-up tests
• Significant medical or psychiatric problems, (including significant renal, hepatic or hematologic dysfunction) which would make the individual a poor protocol candidate
• Use of any investigational agent within the last 3 months, or at the discretion of the medical monitor
• History of pelvic radiation
• RANDOMIZATION EXCLUSION CRITERIA:
• Anticipated colectomy within eight months of randomization; the results of the initial endoscopies, including pathology reports and blood tests will be reviewed by the study endoscopist and surgeon prior to initiation of drug treatment to determine if the patient can remain on study
• Discrete gastric or duodenal ulcer of size > 5 mm; patients with Helicobacter pylori related peptic ulcers of > 5 mm at the time of the baseline endoscopy will become eligible upon endoscopically documented successful treatment of Helicobacter pylori and of the ulcer(s).
• Hemoglobin (Hgb) < 10.0 gm/dl
• Platelet count < 100,000/ml
• White blood cell (WBC) with differential < 3,000/ml
• Serum glutamate pyruvate transaminase (SGPT) > 1.5 x upper limit of normal, serum glutamic oxaloacetic transaminase (SGOT) > 1.5 upper limit of normal
• Alkaline phosphatase > 1.5 x upper limit of normal
• Bilirubin > 2 x upper limit of normal
• Creatinine > 1.5 x upper limit of normal
• Has had a positive serum pregnancy test within 14 days prior to baseline randomization
• Known or prior coagulopathy
• Elevated C-reactive protein (CRP) (> 3.0 mg/L)
• History of cardiovascular diseases or risk factors that might include one of the following: myocardial infarction, angina, coronary angioplasty, congestive heart failure, stroke, or coronary bypass surgery
• Uncontrolled hypertension (> 135/> 85 mm Hg on three repeated measurements during the 6 weeks prior to enrollment on the study); this pertains to subjects with known diagnosis of hypertension; such subjects will have been invited to participate in the trial following successful treatment of their known hypertension; subjects with diagnosis of hypertension established at study entry will be considered cases of potential "white coat" hypertension; such subjects will be otherwise evaluated for protocol and randomized if they agree to be monitored for blood pressure (BP); if BP remains persistently elevated, subjects will be allowed to remain on-study for three months while undergoing antihypertensive therapy and monitoring; if, at the end of 3 months, subjects cannot demonstrate successful BP control as measured and documented locally, dosing will be suspended; such subjects will nevertheless be urged to complete 6-month off study evaluation, for intention to treat analysis
• Family history of premature coronary disease (i.e. onset < 55 years of age)
• Uncontrolled diabetes; subjects with preexisting diagnosis of diabetes will be eligible to participate in the trial if able to document acceptable management by their treating physician; subjects with diagnosis of diabetes established at study entry will be considered cases of new onset disease; such subjects will be otherwise evaluated for protocol and randomized if they agree to blood sugar monitoring; if glucose remains persistently elevated, subjects will be allowed to remain on-study for three months while undergoing therapy and monitoring; of, at the end of 3 months, subjects cannot demonstrate successful glucose control as measured and documented locally, dosing will be suspended; such subjects will nevertheless be urged to complete 6-month off study evaluation, for intention to treat analysis
• Uncontrolled hypercholesteremia (low-density lipoprotein cholesterol [LDL-C] > 130); hypercholesteremia needs to be controlled following the updated National Cholesterol Education Program Adult Treatment Panel III Guidelines for at least 3 months prior to enrollment on the study; hypercholesteremia treatment should continue during the entire period of Celecoxib treatment on the protocol; this pertains to subjects with known diagnosis of hypercholesterolemia; such subjects will have been invited to participate in the trial following successful treatment of their elevated cholesterol; subjects with diagnosis of hypercholesterolemia established at study entry will be considered cases of new onset disease; such subjects will be otherwise evaluated for protocol and randomized if they agree to cholesterol treatment and monitoring; subjects will be allowed to remain on-study for three months while undergoing therapy and monitoring; if, at the end of 3 months, subjects cannot demonstrate successful cholesterol control as measured and documented locally, dosing will be suspended; such subjects will nevertheless be urged to complete 6-month off study evaluation, for intention to treat analysis

• Metabolic syndrome diagnosis; the diagnosis of metabolic syndrome is made when three or more of these risk factors are present:

  • Waist circumference: Men > 102 cm (> 40 in.); women > 88 cm (> 35 in.)
  • Triglycerides > 150 mg/dl ( > 1.69 mmol/L)
  • High-density lipoprotein cholesterol (HDL-C): Men < 40 mg/dl (< 1.03 mmol/L), women < 50 mg/dl (< 1.29 mmol/L)
  • Blood pressure > 130/85 mm Hg
  • Fasting glucose > 110 mg/dl (> 6.1 mmol/L)
• History of deep venous thrombosis, pulmonary embolism, systemic lupus erythematous, family history of protein S or C deficiencies, prior heparin-induced thrombocytopenia, Factor V Leiden deficiencies or high homocysteine levels
• Any indications for acetylsalicylic acid (ASA)

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 65 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States
• Removed Location Countries: United Kingdom

Administrative Information

• NCT Number: NCT00033371
• Other Study ID Numbers: NCI-2013-00844; NCI-2013-00844 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); N01-CN95040; CDR0000069278; NCI-P02-0219; ID00-109 ( Other Identifier: MD Anderson Cancer Center ); P30CA016672 ( U.S. NIH Grant/Contract ); MDA-ID-00109 ( Other Identifier: MD Anderson Cancer Network ); N01-CN-95040 ( Other Identifier: DCP ); N01CN95040 ( Other Identifier: US NIH Grant/Contract Award Number )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: National Cancer Institute (NCI)
• Study Sponsor: National Cancer Institute (NCI)
• Collaborators: Not Provided

Investigators

• Principal Investigator: Patrick Lynch; MD Anderson Cancer Network

• PRS Account: National Cancer Institute (NCI)
• Verification Date: September 2020